Research ArticleArticle
Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
Shahin Jamal, Marie Hudson, Aurore Fifi-Mah and Carrie Ye
The Journal of Rheumatology July 2019, jrheum.190084; DOI: https://doi.org/10.3899/jrheum.190084
Shahin Jamal
From the Division of Rheumatology, Vancouver General Hospital, and Department of Medicine, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Jewish General Hospital and Lady Davis Institute; Department of Medicine, McGill University, Montreal, Quebec; Division of Rheumatology, University of Calgary, Calgary; Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. S. Jamal, MD, MSc, Division of Rheumatology, Vancouver General Hospital, and Department of Medicine, University of British Columbia; M. Hudson, MD, MPH, Division of Rheumatology, Jewish General Hospital and Lady Davis Institute; A. Fifi-Mah, MD, Division of Rheumatology, University of Calgary; C. Ye, MD, Division of Rheumatology, Department of Medicine, University of Alberta. Address correspondence to Dr. S. Jamal, 2775 Laurel Ave., Suite 8205B, Vancouver, British Columbia V5Z 1M9, Canada. E-mail: Shahin.jamal@vch.ca. Accepted for publication June 28, 2019.
Marie Hudson
From the Division of Rheumatology, Vancouver General Hospital, and Department of Medicine, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Jewish General Hospital and Lady Davis Institute; Department of Medicine, McGill University, Montreal, Quebec; Division of Rheumatology, University of Calgary, Calgary; Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. S. Jamal, MD, MSc, Division of Rheumatology, Vancouver General Hospital, and Department of Medicine, University of British Columbia; M. Hudson, MD, MPH, Division of Rheumatology, Jewish General Hospital and Lady Davis Institute; A. Fifi-Mah, MD, Division of Rheumatology, University of Calgary; C. Ye, MD, Division of Rheumatology, Department of Medicine, University of Alberta. Address correspondence to Dr. S. Jamal, 2775 Laurel Ave., Suite 8205B, Vancouver, British Columbia V5Z 1M9, Canada. E-mail: Shahin.jamal@vch.ca. Accepted for publication June 28, 2019.
Aurore Fifi-Mah
From the Division of Rheumatology, Vancouver General Hospital, and Department of Medicine, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Jewish General Hospital and Lady Davis Institute; Department of Medicine, McGill University, Montreal, Quebec; Division of Rheumatology, University of Calgary, Calgary; Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. S. Jamal, MD, MSc, Division of Rheumatology, Vancouver General Hospital, and Department of Medicine, University of British Columbia; M. Hudson, MD, MPH, Division of Rheumatology, Jewish General Hospital and Lady Davis Institute; A. Fifi-Mah, MD, Division of Rheumatology, University of Calgary; C. Ye, MD, Division of Rheumatology, Department of Medicine, University of Alberta. Address correspondence to Dr. S. Jamal, 2775 Laurel Ave., Suite 8205B, Vancouver, British Columbia V5Z 1M9, Canada. E-mail: Shahin.jamal@vch.ca. Accepted for publication June 28, 2019.
Carrie Ye
From the Division of Rheumatology, Vancouver General Hospital, and Department of Medicine, University of British Columbia, Vancouver, British Columbia; Division of Rheumatology, Jewish General Hospital and Lady Davis Institute; Department of Medicine, McGill University, Montreal, Quebec; Division of Rheumatology, University of Calgary, Calgary; Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. S. Jamal, MD, MSc, Division of Rheumatology, Vancouver General Hospital, and Department of Medicine, University of British Columbia; M. Hudson, MD, MPH, Division of Rheumatology, Jewish General Hospital and Lady Davis Institute; A. Fifi-Mah, MD, Division of Rheumatology, University of Calgary; C. Ye, MD, Division of Rheumatology, Department of Medicine, University of Alberta. Address correspondence to Dr. S. Jamal, 2775 Laurel Ave., Suite 8205B, Vancouver, British Columbia V5Z 1M9, Canada. E-mail: Shahin.jamal@vch.ca. Accepted for publication June 28, 2019.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
Shahin Jamal, Marie Hudson, Aurore Fifi-Mah, Carrie Ye
The Journal of Rheumatology Jul 2019, jrheum.190084; DOI: 10.3899/jrheum.190084